Cardiac Science - 500 Beiträge pro Seite

[Teerwerk]

Wie geht es mit dieser Aktie (Firma stellt Defibrillatoren her) weiter? Gibt es schlechte Unternehmenszahlen, denn der Kurs hat in letzter Zeit nachgegeben? Wer weiß mehr?

[Dolocher]

Eigentlich gibt es zu dieser Aktie im Moment eher positives zu berichten in Kurzform z.B.

wurde am 4. August der neue Powerheart AED G3 von der FDA zugelassen,welche sich durch eine konkurrenzlose neue Technologie und eine absolut fortschrittliche Software auszeichnet
Der Marktanteil beläuft sich zur Zeit auf etwa 25%
Umsatz derzeit ~200Mio US$ bis 2006 werden ~650 Mio erwartet
Gerade wurden grössere Aufträge von z.B. U.S.Postal Service, Alabama National Guard Army,Departement of Mental Health des Staates Texas im Umfang von c.a. 1500 Geräten!
Vor einigen Wochen kam die Meldung, das Barton Protective Services die Powerhearts in seinen Geschäftsstellen installiert und seinen weit über 1000 Kunden das gleiche empfehlen wird.
zum Verständnis: Barton ist ein USA-Landesweiter Sicherheitsdienst,der Einkaufszentren,Wohnkomplexe,Krankenhäuser und Firmengebäude beschützt
General Electric!! ist eben mit DFIB eine mehrjährige Vertriebs-und Entwicklungskooperation eingegangen
Die GE-Tochter GE Medical Systems soll den Vertrieb in Europa,Asien und mittleren Osten übernehmen

Fürs laufende Jahr wird noch mit einem Verlust von 0,09 US$ erwartet
!!! aber für 2004 wird ein Gewinnsprung von 222% auf einen Gewinn von 0,11 US$ pro Aktie erwartet


Quelle: Taipan Nr. 11/2003

Bei diesen positiven Aussichten ist m.E. momentan ganz sicher der Boden gefunden und das langfristige Kursziel wurde von "Taipan" auf c.a. 10,25 US$ angegeben.

Ich hoffe,das hilft Dir etwas weiter.

MfG

[alexis74]

immerhin etwas

[Dolocher]

Noch was für alle,die ebenfalls einen Kauf in betracht ziehen oder,wie ich die Position aufstocken wollen:

Quartalszahlen sollen gut ausgefallen sein,hab leider selbst noch keine gesehen,aber eigentlich wurden die guten Zahlen ja auch erwartet,also keine Überraschung.

Taipan empfiehlt übrigens einen erneuten Kaufkurs von 3,38 US$

Muss nun jeder für sich entscheiden,wo der Einstieg günstig ist,mittel-bis langfristig macht man bei aktuellen Kursen sicher nichts falsch, da die Aussichten recht positiv sind und einige grosse Aufträge vorhanden sind,so das wir in 12 Monaten an dieser Stelle über 5,50 - 6,50 US$ sprechen können.

MfG

[Dolocher]

CARDIAC SCIENCE ANNOUNCES 2003 THIRD QUARTER, NINE-MONTH RESULTS
AED Revenue for Quarter Up 57%, Operating Loss Cut by 91%


IRVINE, CA (October 28, 2003) -- Cardiac Science, Inc. (Nasdaq: DFIB), a leading manufacturer of life-saving automated public access defibrillators (AEDs) and provider of comprehensive AED/CPR training and AED program management services, today reported revenue of $15.7 million for the third quarter ended September 30, 2003 as compared to $13.6 million in the same period last year. Sales of AEDs and related accessories in the third quarter totaled $15.0 million representing an increase of 57 percent over the prior year quarter. For the nine months, sales of AEDs and related accessories totaled $40.4 million and were up 56 percent over the same period last year. At quarter end, the Company had an order backlog of $630,000, due primarily to higher-than-expected demand for the new Powerheart® AED G3 product line released for commercial sale in August.

The gross margin for the third quarter of 2003 increased to 60.5 percent from 50.0 percent in the same prior year period and was up sequentially from 57.2 percent in the second quarter of 2003.

The company narrowed its operating loss significantly to $264,000 in the third quarter of 2003, compared to a $2.8 million loss in the same period last year, and down from the $621,000 operating loss in the 2003 second quarter. The net loss in the third quarter decreased to $1.5 million, or a $0.02 loss per share, down from $4.1 million, or a $0.06 loss per share, in the corresponding prior year period.

Revenue for the nine months ended September 30, 2003 was $44.3 million, a 24 percent increase over the $35.8 million for the year-earlier period. The net loss for the nine months was $6 million, or a $0.09 loss per share, as compared to $11.4 million, or a $0.17 loss per share, in 2002.

Cardiac Science Chairman and CEO Raymond W. Cohen said, “Customer demand for our new Powerheart® AED G3 and FirstSave® AED G3 devices exceeded our expectations and most customers purchased our flagship device, the Powerheart AED G3. Although we limited sales of the new generation AEDs to the U.S. market, nearly 60 percent of the all AEDs sold were the new generation products which challenged our ability to fill demand within the quarter. The result was a strong sequential increase in gross margin between the second and third quarters and a backlog of unfilled orders moving into the fourth quarter. Had we been able to ship all orders, we would have achieved our objective of operating profitability in the third quarter.”

In the third quarter, more than 8,000 AED units were sold to a wide variety of market segments worldwide, representing an increase in unit sales of 82 percent as compared to the 4,400 devices sold in the same period last year. The two strongest sectors within the domestic AED market were corporate workplaces and municipalities. Combined, these segments accounted for over 78 percent of the total number of AEDs sold in the United States. International AED sales were up 122 percent over the prior year period and accounted for 16 percent of the quarter`s total AED revenue.

In the quarter, sales of Diascope® patient monitors to international distributors totaled $210,000 as compared to $3.6 million in corresponding 2002 period. During the 2002 period, the Company sold off the remaining inventory produced in its manufacturing facility in Denmark, which was shut down during third quarter 2002. This quarter, International demand for our Diascope monitors, especially in the Middle East, where the company has sold the majority of those units, was again weak as instability and poor economic conditions continued to delay buying decisions in those countries. Sales of disposable defibrillator pads and equipment related to deployment of the Powerheart CRM product in the hospital market was $238,000 in the third quarter of 2003.

About Cardiac Science

Cardiac Science develops, manufactures and markets Powerheart®-brand public-access defibrillators (AEDs) and offers comprehensive AED/CPR training and program management services that facilitate successful deployments. The Company also manufactures its AED products on a private label basis for other leading medical companies. Cardiac Science`s AEDs, Diascope®-brand patient monitors and Powerheart® CRM™, the only FDA-cleared therapeutic patient monitor that instantly and automatically treats hospitalized cardiac patients who suffer life-threatening heart rhythms are marketed in the United States by its 55-person sales force, numerous domestic distribution channel partners and by international distributors in more than 50 countries around the world. For more information, please visit www.cardiacscience.com.

This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Cardiac Science cautions that these statements are subject to substantial risks and uncertainties and are qualified by important factors that could cause actual results to differ materially from those reflected by the forward-looking statements and should not be relied upon by investors when making an investment decision. Information on these and other factors is detailed in the Company`s Form 10-K for the year ending December 31, 2002, subsequent quarterly filings, and other documents filed by the Company with the Securities and Exchange Commission.

[udoernst]

eigentlich gibt es nur gutes zu vermelden....
DFIB teilte gestern mit: $550.000 neuer umsatz, großaufträge von der regierung ...

nutzt im moment alles nicht, weil der kurs durch einige analystenhäuser gedeckelt wird...

[udoernst]

hier die details:

"Cardiac Science Announces $550,000 in Sales for AED Product, ... Alle Nachrichten

04.12. / 07:34



< zurück <



> Archiv >



Druckversion


IRVINE, Calif., Dec. 4 /PRNewswire-FirstCall/ -- Cardiac Science, Inc. , a leading manufacturer of life-saving automated public access defibrillators (AEDs), today announced that it has closed a number of transactions with leading corporate and government customers that include the purchase of Powerheart G3 AEDs, training and program management services. In aggregate, the sales totaled more than $550,000. Included are orders from Weyerhaeuser Company, ALCOA, Inc., Harrah``s Entertainment, Inc., The U.S. Postal Service and the U.S. Equal Employment Opportunity Commission (EEOC). These sales have been driven by Cardiac Science``s decision to provide AED and CPR training and program management services through its acquisition of Complient Corporation.

"We believe these new orders from leading U.S. corporations and government agencies are indicative of their recognition of the value of a one-stop-shop approach to AED procurement and deployment," said Raymond W. Cohen, Chairman and CEO of Cardiac Science.

"The acquisition of Complient Corporation in October is beginning to yield immediate and tangible results. Our ability to offer a comprehensive package of AED equipment and provide high-quality training for hundreds of employees along with program management services for multiple facilities in numerous cities saves our customers from numerous logistical headaches. We believe our new and expanded offering will help us secure many additional customers in the majority of the markets we serve."

Harrah``s Entertainment purchased a total of 100 AEDs and 20 program management suites for deployment and training for its Casino properties across the USA. The U.S. Postal Service bought 80 AEDs along with 37 program management suites for geographically diverse locations. Weyerhaeuser purchased 35 AEDs plus supporting management and training services for 15 U.S. facilities and ALCOA is outfitting 18 of their domestic facilities with AEDs and training. Cardiac Science won a contract with EEOC to manage its AED program, supply AEDs and train EEOC employees in 24 of its largest district offices. EEOC has now deployed AEDs in approximately half of their total number of facilities and intends to implement AED programs in its remaining facilities nationwide.

About Cardiac Science

Cardiac Science develops, manufactures and markets Powerheart(R)-brand public-access defibrillators (AEDs) and offers comprehensive AED/CPR training and program management services that facilitate successful deployments. The Company also manufactures its AED products on a private label basis for other leading medical companies. Cardiac Science``s AEDs, Diascope(R)-brand patient monitors and Powerheart(R) CRM(TM), the only FDA-cleared therapeutic patient monitor that instantly and automatically treats hospitalized cardiac patients who suffer life-threatening heart rhythms are marketed in the United States by its 55-person direct sales force, numerous domestic distribution channel partners and by international distributors in more than 50 countries around the world. For more information, please visit http://www.cardiacscience.com/ .

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Cardiac Science cautions that these statements are subject to substantial risks and uncertainties and are qualified by important factors that could cause actual results to differ materially from those reflected by the forward-looking statements and should not be relied upon by investors when making an investment decision. Information on these and other factors is detailed in the Company``s Form 10-K for the year ending December 31, 2002 and other documents filed by the company with the Securities and Exchange Commission.

For further information, please contact: investors, Matt Clawson, [e-mail] , or media, Len Hall, [e-mail] , both of Allen & Caron Inc, [phone]; or Michael Gioffredi, VP Sales & Marketing of Cardiac Science, Inc., [phone], [e-mail] .

[Teerwerk]

Hoffen wir, dass die Aktie dann im neuen Jahr wieder zulegen wird.

[udoernst]

na, ich denke, dass sie eher zulegen wird...

[Dolocher]

Es geht ganz sicher nach oben,allerdings versuche ich schon seit 2 Wochen unter 3,40 US$ reinzukommen und hatte bisher keinen Erfolg...bleibt die Hoffnung auf fallende Kurse am Montag ,aber danach kann DFIB richtig starten.
Bei den Aussichten ist der Kursverlauf der letzen Tage und Wochen schon sehr unverständlich

[udoernst]

na wer sagt`s denn..... über 10% plus zur eröffnung..das ist doch schon mal was!

[Dolocher]

Toll,

bin Freitag zu 3,35 rein
Irgendwann muss doch das Potenzial dieses Wertes auch von den Anlegern erkannt werden!

[udoernst]

ich hatte schon fast vermutet, du wärst nicht mehr zum zug gekommen....jetzt sogar schon 18 % im plus...

weiß jemand was genaueres? kann ja nicht nur ne technische reaktion sein, oder?

[udoernst]

dfib: aktuelle kaufempfehlung von americanbulls.com!

start frei!

[Dolocher]

Ich habe auch sehr lange gewartet und riskiert,den Zug zu verpassen,aber dann standen wir Freitag Abend plötzlich nochmal bei 3,30US$
aktuell: 4,13 ich liebe diese Aktie und bin 100% bullish!
Was den Kursanstieg ausgelöst hat,weiss ich nicht,zumindest gibt es keine News.Entweder reicht die o.g. Empfehlung oder die Anleger haben endlich gemerkt,welche Chancen dieser Wert bietet.
Bleibt nur zu hoffen,das hier nicht zu viele Zocker am Werke sind,was bei solchen Kurssprüngen allerdings zu befürchten ist...

Viel Glück allen Investierten!

[udoernst]

ob der skontrenführer in ffm heute noch mal aufwacht?
dfib gibts im moment weit unter parität!

[udoernst]

..spät aber immerhin,
jetzt weiß ich auch, was am 8.12. den kurssprung ausgelöst hat. dfib hat ein patent auf seine mobilen defibs bekommen.
Die erste vollautomatische Version der Powerheart AED G3 Defibrillatoren sollen erstmals im ersten Quartal 2004 auf den Markt kommen.

[Dolocher]

Langsam scheint DFIB auch bei den Instis wieder interessanter zu werden,laut Thomson Financial im letzten Monat immerhin 7% vom Trade Volumen durch Institutionelle Anleger,Tendenz steigend.Hoffentlich hilft uns das im nächsten Jahr und vor allem setze ich,wie wahrscheinlich die meisten Investierten im nächten Jahr auf den neuen Powerheart AED G3.

@udoernst
Das wurde auch langsam Zeit,nachdem die Zulassung durch die FDA bereits am 4.August erfolgte und die Sicherung des Patents auch die einzigartige Marktstellung von DFIB sicherstellt.Leider habe ich diese Meldung nicht gefunden,wäre nett,wenn Du diese hier irgendwie noch reinstellen könntest.

MfG

[udoernst]

IRVINE, Calif., Dec. 8 /PRNewswire-FirstCall/ -- Cardiac Science, Inc. announced today it was granted a U.S. patent that covers a publicly-available portable defibrillator capable of being used by a bystander to automatically deliver life-saving defibrillation shock(s) to a heart attack victim.

The issuance of the patent preludes the first quarter 2004 launch of Cardiac Science``s fully-automatic version of its Powerheart(R) AED G3. This new version AED only requires that someone properly attach the AED to a heart attack victim in distress. No additional action is required by the rescuer since the device will analyze the patient``s condition to detect a life-threatening heart rhythm and, if appropriate, deliver the life-saving defibrillation shock(s) to restore the victim``s heart to a normal rhythm.

This patent, No. 6,658,290, titled "Public Access Defibrillator" brings the total number of issued patents to 73 that Cardiac Science owns relating to a wide variety of external defibrillation technologies for use in public access and the hospital bedside.

Cardiac Science Chairman and CEO Raymond W. Cohen said that the rescue of a sudden cardiac arrest victim could not get any easier than merely attaching this device and letting it do its job.

"The timing of securing this broad intellectual property asset is quite advantageous since we have completed the product development work and plan to launch a fully-automatic AED device in a few months upon FDA clearance of our 510(k) filing," Cohen said. "We believe that this new public-access AED will be attractive to buyers in the municipal, corporate and home market who are deploying AEDs where Good Samaritan bystanders or minimally-trained rescuers may be called upon to use these devices."

About Cardiac Science

Cardiac Science develops, manufactures and markets Powerheart(R)-brand public-access defibrillators (AEDs) and offers comprehensive AED/CPR training and AED program management services that facilitate successful deployments. The Company also manufactures its AED products on a private label basis for other leading medical companies. Cardiac Science``s AEDs, Diascope(R)-brand patient monitors and Powerheart(R) CRM(TM), the only FDA-cleared therapeutic patient monitor that instantly and automatically treats hospitalized cardiac patients who suffer life-threatening heart rhythms are marketed in the United States by its 55-person direct sales force, numerous domestic distribution channel partners and by international distributors in more than 50 countries around the world. For more information, please visit http://www.cardiacscience.com/

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Cardiac Science cautions that these statements are subject to substantial risks and uncertainties and are qualified by important factors that could cause actual results to differ materially from those reflected by the forward-looking statements and should not be relied upon by investors when making an investment decision. Information on these and other factors is detailed in the Company``s Form 10-K for the year ending December 31, 2002 and other documents filed by the company with the Securities and Exchange Commission.

Contact: Matt Clawson (Investors) Kenneth Olson Len Hall (Media) Chief Technology Officer Allen & Caron Inc Cardiac Science, Inc. [phone] [phone] [e-mail] [e-mail] [e-mail]

Cardiac Science, Inc.

[Dolocher]

Danke!

FFM zu Handelsende immer noch 15% unter Parität,aber der Wert wird in D generell mit recht niedrigen Umsätzen gehandelt,so dass ein Kauf eher in USA zu empfehlen ist,was zwar einen Währungseffekt beinhaltet,der sich allerding in einem zusätzlichen Gewinn auszahlen könnte,falls der Dollar irgendwann seine Talfahrt beendet und wieder an Wert gewinnt,was ich ab mitte des nächsten Jahres für möglich halte.

[Lekaro]

IRVINE, Calif., Dec. 29 /PRNewswire-FirstCall/ -- Cardiac Science, Inc. , a leading manufacturer of life-saving automated public access defibrillators (AEDs), today announced that the Kissimmee Police Department in Kissimmee, FL has purchased Cardiac Science Powerheart(R) Automated External Defibrillators (AEDs) for its police vehicles and also became the first police department to purchase the Company``s comprehensive AED training and program management services. More than 200 Kissimmee police officers and civilian employees will receive training in the use of AEDs as part of Cardiac Science``s "Heartsafe AED Training Program" and other members of the department will be trained and equipped with the record keeping and compliance package that is part of the complete program.

An initial order of 50 AEDs will be deployed in marked Kissimmee police cars with the goal of the department to outfit all 87 cars in the coming months, said Police Chief Mark Weimer, whose department provides police services for the town of 52,000 people in central Florida. Chief Weimer added that the complete training, record keeping and program management package, along with the easy to use and deploy Powerheart AEDs, convinced him to choose the Powerheart over the other AEDs on the market.

"Cardiac Science provided us with a packaged solution that was perfect for our full AED deployment and procurement needs," Chief Weimer said. "Not only are we ecstatic about having these AED devices in our patrol cars, giving our officers the opportunity to save members of our community who suffer from massive heart attacks, but we are also getting the essential training and record-keeping aspects of the program. No one else offered us the complete program."

Cardiac Science Chairman and CEO Raymond W. Cohen said that the city of Kissimmee, like other government and corporate customers, have found the Company``s complete training and program management package a unique one-stop solution to their AED needs.

"City officials and business leaders are recognizing that not only do they need AED devices to protect their citizens and employees, but they also need the training and management services we offer as part of our Heartsafe AED Training Program. This service is a direct result of our recent acquisition of Complient Corporation and, in these days of tight budgets and shrinking municipal staffs, we believe our ability to outsource the management of an AED program can make the difference in winning contracts such as this one."

[Dolocher]

öfter mal was neues


Cardiac Science, Inc., (DFIB), a manufacturer of automated public access defibrillators (AEDs), announced that it has closed a number of transactions with leading corporate and government customers that include the purchase of Powerheart G3 AEDs, training and program management services.

In aggregate, the sales totaled more than $550,000. Included are orders from Weyerhaeuser Company, ALCOA, Inc., Harrah`s Entertainment, Inc., The U.S. Postal Service, and the U.S. Equal Employment Opportunity Commission (EEOC). These sales have been driven by Cardiac Science`s decision to provide AED and CPR training and program management services through its acquisition of Complient Corporation.

"We believe these new orders from leading U.S. corporations and government agencies are indicative of their recognition of the value of a one-stop-shop approach to AED procurement and deployment," said Raymond W. Cohen, chairman and CEO of Cardiac Science.

"The acquisition of Complient Corporation in October is beginning to yield immediate and tangible results. Our ability to offer a comprehensive package of AED equipment and provide high-quality training for hundreds of employees along with program management services for multiple facilities in numerous cities saves our customers from numerous logistical headaches. We believe our new and expanded offering will help us secure many additional customers in the majority of the markets we serve."

Harrah`s Entertainment purchased a total of 100 AEDs and 20 program management suites for deployment and training for its Casino properties across the USA. The U.S. Postal Service bought 80 AEDs along with 37 program management suites for geographically diverse locations. Weyerhaeuser purchased 35 AEDs plus supporting management and training services for 15 U.S. facilities and ALCOA is outfitting 18 of their domestic facilities with AEDs and training. Cardiac Science won a contract with EEOC to manage its AED program, supply AEDs, and train EEOC employees in 24 of its largest district offices. EEOC has now deployed AEDs in approximately half of their total number of facilities and intends to implement AED programs in its remaining facilities nationwide. This article was prepared by Biotech Week editors from staff and other reports.

[Lekaro]

...und noch ein Auftrag!!!

IRVINE, Calif., Jan. 5 /PRNewswire-FirstCall/ -- Cardiac Science, Inc. , a leading manufacturer of life-saving automated public-access defibrillators (AEDs) and provider of comprehensive AED/CPR training and AED program management services, today announced that the states of Arizona, Michigan, Texas and Wyoming selected the Company``s Powerheart(R)-brand automated external defibrillators (AEDs) for deployment throughout their rural communities in fire and emergency services vehicles, community facilities and regional health care centers.

In aggregate, the four states purchased more than 400 AEDs with $740,000 in grant money. Funding for the AEDs was made available through Federal grants provided under the Congressional Rural Access to Emergency Devices Act.

Jim Mayberry, Program Director for Wyoming``s Office of Emergency Medical Services, who is administering the grant for that state and is helping to place the AEDs, selected Powerhearts for the second year in a row after once again reviewing the other devices on the market.

"We chose Cardiac Science AEDs based on value, the fact that the service Cardiac Science provided was great last year and because we feel their device is the best AED on the market," Mayberry said.

Cardiac Science Chairman and CEO Raymond W. Cohen said the selection of his Company``s AED devices and services "underscores the technological superiority of our devices and the diligent work of our sales and service team to ensure customer satisfaction."

"We worked very hard to win these state contracts and we``re proud that Cardiac Science was selected as their exclusive provider of AEDs for facilities in rural communities," Cohen said. "Emergency service providers recognize the value of AEDs as critical life-saving devices. Every day in the U.S. and around the world, buyers of AEDs are arriving at the same conclusions -- Cardiac Science is committed to customer satisfaction, Powerheart(R) AEDs are the most reliable and easiest AEDs to use and offer the best value for the money."

[udoernst]

und kein kleiner..... freu!!

[Lekaro]

na ja, neue Absatzwege werden ab heute auch beschritten....

AED.com to Offer Online AED Sales and Service Packages for Home, Schools and Small Business

IRVINE, Calif., Jan. 6 /PRNewswire-FirstCall/ -- Cardiac Science, Inc. (Nasdaq: DFIB, news), a leading manufacturer of life-saving automated public access defibrillators (AEDs), announced today that it has commenced direct sales of AED products and services via its affiliated website http://www.AED.com. In October 2003, the company launched the Internet site as a one-stop resource for consumers interested in current news and information on AED deployment, legislation, grants, operation, training and products. Until today, the site has not been a commercial product outlet.




AED.com now offers individual consumers, schools and small businesses a convenient way to purchase Cardiac Science Powerheart®-brand AEDs online and arrange for comprehensive AED/CPR training services, AED program management and medical direction. An AED grant application is also available online for qualifying non-profit organizations to purchase AEDs at a reduced price.

Cardiac Science Chairman and CEO Raymond W. Cohen said, "Consumer response and interest in AED.com since its launch in October has been outstanding. Offering consumers the ability to purchase AEDs directly from us over the internet along with requisite medical direction and training allows us to make it easier for consumers to readily acquire this life-saving technology. We believe that these advantages will facilitate our entry into the growing home AED market."

Cohen continued, "AED.com is quickly becoming the definitive resource on the internet for everything related to AEDs and how to successfully deploy them. We see AED.com as the education and marketing vehicle that allows us to better inform the public about the danger of sudden cardiac arrest and the life-saving potential of AEDs, as well as a new distribution channel capable of generating revenue from the direct sale of AEDs to consumers."


About AED.com


AED.com provides education to anyone seeking information on the use and deployment of automated public access defibrillators. The site operates as a convenient portal for consumers who want to purchase AEDs or have already deployed AEDs, and offers comprehensive AED program management, AED/CPR training services and device accessories and replacement parts. AED.com is rich in content in areas of AED legislation, training and products and is organized for easy navigation. It includes personal accounts from lay rescuers and first responders as well as people whose lives have been saved by AEDs. In addition it provides links to the various foundations and non-profits active in the donation of AEDs. For more information, please visit http://www.aed.com.

[Lekaro]

Der Kurs steigt langsam aber stetig

IRVINE, Calif., Jan. 8 /PRNewswire-FirstCall/ -- Cardiac Science, Inc. , a leading manufacturer of life-saving automated public-access defibrillators (AEDs), today announced that it has been awarded multi-year contracts by several of the world``s largest pharmaceutical manufacturers including AstraZeneca, Schering-Plough and Wyeth to supply Powerheart(R) AEDs and provide comprehensive training and program management services for facilities in various locations throughout the U.S. and Puerto Rico.

In aggregate, the total value of the contracts signed with London-based AstraZeneca, Plc., Kenilworth, N.J.-based Schering-Plough, and Madison, N.J.-based Wyeth exceeded $725,000.

More than 130 AEDs were shipped in the fourth quarter of 2003 to 30 facilities in 12 states and Puerto Rico. AED/CPR and first-aid training will be provided to all three customers beginning this month and program management services will continue in coming years and as far out as 2008 for one of the companies. Specific deployment locations of the AEDs varied by customer and will include executive offices, research and development facilities, manufacturing, shipping and receiving and administrative locations.

Cardiac Science``s Chairman and CEO Raymond W. Cohen stated the Company``s ability to establish long-term relationships with large multinationals with numerous facilities in locations in the US and around the world has been greatly enhanced by the Company``s recent acquisition of Complient.

"The long-term nature of these contracts is especially encouraging," said Cohen. "Having the capability and infrastructure to successfully deliver a comprehensive package of AED equipment, training and program management services has resulted in a powerful value proposition for large customers and significant recurring revenue opportunities for Cardiac Science. In just a few short months we have managed to position ourselves as an important partner to these organizations, not merely a one-off seller of a product. As a result we have already built a list of clients that will require products and services for years to come."

[Teerwerk]

Aktie steigt langsam an. Jetzt 3,80 Euro.

[Lekaro]

IRVINE, Calif., Jan. 15 /PRNewswire-FirstCall/ -- Cardiac Science, Inc. , a leading manufacturer of life-saving automated public-access defibrillators (AEDs) and provider of comprehensive AED/CPR training and AED program management services, today announced that it has entered into a national training agreement with the American Heart Association. This agreement establishes Cardiac Science as an American Heart Association- approved National Training Center and authorizes the Company to conduct and administer American Heart Association-accredited training courses in basic life support and emergency cardiovascular care and provide the Association``s educational materials for its customers throughout the nation.

American Heart Association Vice President, Emergency Cardiovascular Care Programs Mike Bell said "With 150 certified educators nationwide, Cardiac Science has unique capabilities and infrastructure. We envision Cardiac Science training and certifying over 200,000 people in corporate and government workplaces in 2004 thereby making a significant contribution to strengthening the ``Chain of Survival`` initiative -- programs endorsed by the American Heart Association that are designed to streamline local access to CPR, AEDs and hospital care."

"Subsequent to our recent acquisition of Complient, Cardiac Science is the only AED maker with the ability to provide a turn-key package for AED procurement, deployment, AED program management and cardiac emergency training. This agreement puts us on track toward becoming the single largest national American Heart Association training center in America," said Cardiac Science Chairman and CEO Raymond W. Cohen. "We are enthusiastic about our partnership with the American Heart Association and adding the Association``s training curriculum and materials as part of our comprehensive HeartSafe(TM) Workplace Program."

About Sudden Cardiac Arrest (SCA) and AEDs

Currently 95 percent of SCA victims die before reaching the hospital due to the length of time it takes for emergency personnel to arrive on the scene. In all, about 340,000 Americans die each year from SCA. In fact, a person``s chance of survival is reduced by about 10 percent for every minute spent waiting for a potentially life-saving defibrillation shock. Implementation of a successful public access defibrillation program has achieved survival rates as high as 74 percent if patients received defibrillation within 3 minutes. The American Heart Association estimates that as many as 50,000 of these lives can be saved if an automated external defibrillator is available at the time of the emergency, and someone is nearby who has been trained to use it.

AEDs are becoming more widely available and are being used in a variety of settings, including airplanes and airports, office buildings, industrial plants, casinos, golf courses, cruise ships, sports arenas and health clubs. In fact, results from the National Heart, Lung and Blood Institute and American Heart Association-sponsored public access defibrillation (PAD) study of automated defibrillators in public places found that deploying AEDs and training citizens to use them can double the chances of surviving SCA.

The PAD study showed that response programs that train lay responders in CPR and AED use, and have AEDs on site, significantly improve survival from cardiac arrest for victims in public settings. During the two year study, 124 cardiac arrests occurred in public facilities where an AED was available and 31 percent of those persons survived versus 17 percent of the 86 arrests that occurred in venues where only conventional responses -- CPR and a call to 911 -- were available.

[Dolocher]

Report from Europe
Report from Europe

COMET trial lauds benefits of carvedilol

A CDU Staff Report

According to the Carvedilol or Metoprolol European Trial (COMET), chronic heart failure (CHF) patients treated with the beta blocking agent carvedilol had a significant survival benefit – 17% better than those taking the selective beta blocker metoprolol. The COMET findings were released last month during the European Society of Cardiology’s (Sophia Antipolis, France) Heart Failure 2003 meeting in Strasbourg, France.

Also published in the July 5 issue of The Lancet, the COMET findings “provide clear evidence of the superior survival benefits of carvedilol over metoprolol in the treatment of chronic heart failure and suggest that carvedilol prolongs the life of patients by 1.4 years compared to metoprolol,” according to Professor Philip Poole-Wilson, chairman of the COMET Steering Committee. “Carvedilol’s significant survival benefit could mean thousands of lives saved each year,” he said, adding that the results “will have a major impact on clinical practice.”

Beta blocking agents are recommended in the guidelines of such major cardiovascular societies as the European Society of Cardiology, the American Heart Association (Dallas, Texas) and the American College of Cardiology (Bethesda, Maryland) for the treatment of mild, moderate and severe CHF. They also have been clinically proven in a number of major clinical trials.

With more than 14,000 patient years of follow-up, COMET is the largest and longest study in CHF and the first head-to-head survival study comparing two beta blocking agents in such patients. The study was focused on determining whether carvedilol was superior in terms of survival to metoprolol in the treatment of CHF patients. Although both are classified as beta blockers, these two drugs have different properties. Carvedilol provides not only Beta-1 receptor blockade, but also blocks Beta-2 and Alpha-1 receptors and displays additional ancillary properties.

Experts in the field suggest that there may be more than 10 million people with CHF in Europe alone. Prognosis for such patients is generally poor, with around half of all of those diagnosed dying within three to five years.

The COMET trial enrolled 3,029 patients from 15 European countries with mild to moderate to severe (New York Heart Association class II-IV) CHF. All were followed up for more than 45 months.

The trial was jointly sponsored by F. Hoffmann-La Roche (Basel, Switzerland) and GlaxoSmithKline (London). Carvedilol is marketed worldwide by Roche under various trade names. It is marketed in North America by GlaxoSmithKline under the name Coreg and in Japan by Daiichi under the trade name Artist.

Direct UK sales force for AED maker

Cardiac Science (Irvine, California) said in June that it has established a direct sales operation in the United Kingdom through the acquisition of LifeTec Medical Ltd. (Timperley, UK), which had been the principal distributor of the company’s automated external defibrillator (AED) products in that country.

The financial terms of the all-cash transaction were not disclosed.

Raymond Cohen, president and CEO of Cardiac Science, said that to date, “our UK network has been competing with direct sales efforts of our competitors and we feel that establishing a direct sales and sales management presence is warranted to ensure that we increase our share of this market.” He said that he “is confident in our ability to grow that business more rapidly and more profitably by taking the operation in house.”

Stuart Hildage, who had been managing director of LifeTec, will continue as managing director of the new Cardiac Science (UK) sales organization. Cardiac Science said that under Hildage’s leadership, LifeTec had captured an estimated 20% share of the AED market in the UK for the company’s Powerheart AED. Cohen referred to the customer base and “rich pipeline of prospects established by LifeTec under Mr. Hildage’s leadership” as “valuable assets” for Cardiac Science as it grows its UK business.

While the new Cardiac Science (UK) sales organization will operate from Lifetec’s existing offices in Timperley, the company said all other functions would be relocated to its international headquarters in Copenhagen, Denmark, in order to leverage the existing operational and administrative infrastructure.

In addition to Powerheart AEDs, Cardiac Science manufactures Diascope brand patient monitors and the Powerheart CRM, which it describes as “the only FDA-cleared therapeutic patient monitor that instantly and automatically treats hospitalized cardiac patients who suffer life-threatening heart rhythms.”

CARDS study halt validates Lipitor

The Collaborative AtoRvastatin Diabetes Study (CARDS) Steering Committee announced last month that a major UK trial studying the reduction of cardiovascular disease (CVD) risk in Type 2 diabetes patients using the cholesterol-lowering medicine Lipitor (atorvastatin) has been stopped early.

The decision to stop the CARDS trial early was made because results collected showed a significant benefit to patients receiving atorvastatin in reducing primary endpoints of major coronary events, stroke or coronary revascularization procedures. The interim results are significant and beyond the early termination threshold agreed for the interim analyses, the steering committee said.

The CARDS study was carried out in the UK and Ireland, involved 2,838 patients and was designed to compare the effectiveness of the lipid-lowering drug, for the primary prevention of cardiovascular disease in diabetic patients with some additional risk factors for CVD. Those given atorvastatin 10 mg were found to have significant reductions in primary endpoints compared to those receiving placebo.

The trial, a collaboration between Diabetes UK, the UK Department of Health and Pfizer UK (Surry, UK), was terminated early because interim analyses confirmed the benefit of treatment. All patients are being notified and will have appropriate study follow-up arranged.

“Stopping this study early is an exciting development,” said Moira Murphy, MD, director of research at Diabetes UK. “Diabetes UK co-sponsored this work in recognition of its potentially critical importance for people with diabetes. We look forward to seeing the analyzed data later this year and hope that it will add to the existing evidence of the benefit statins can have for people with diabetes. People with the condition are up to five times more likely to develop cardiovascular disease, and we should look at the best ways to prevent this.”

“This is the second major atorvastatin trial in the last 12 months which has stopped earlier than anticipated due to benefits over placebo,” said Michael Zaiac, MD, deputy medical director at Pfizer UK.

It is estimated that 1.4 million people in the UK have been diagnosed with diabetes, a figure set to double by 2010. Cardiovascular complications, such as coronary artery disease and stroke, are the principle cause of death in up to 75% of patients with Type 2 diabetes.

Atorvastatin is currently not licensed for the prevention of coronary or cardiovascular events and is a prescription-only medicine.

[Dolocher]

Briefly Noted
Briefly Noted

Quinton, Cardiac Science in agreement

Quinton Cardiology Systems (Bothell, Washington), a developer of advanced cardiology products, and Cardiac Science (Irvine, California), a maker of automated public-access defibrillators, reported an agreement under which Cardiac Science will manufacture its automated external defibrillators (AEDs) for sale by Quinton under the Burdick brand name.

The AEDs, which will be labeled CardioVive, will begin shipping in 3Q03 and will be sold to medical facilities worldwide. According to industry estimates, there are more than 200,000 medical offices and clinics in the U.S. alone. Fewer than 10% are equipped with AEDs.

Burdick, a Quinton subsidiary since January, is a provider of cardiology products and is widely recognized for its strong distribution network focused on physicians’ offices.

SOURCE-Medical Device Daily



© 2004 Dialog, a Thomson business. All rights reserved.

[Lekaro]

IRVINE, Calif., Jan. 20 /PRNewswire-FirstCall/ -- Cardiac Science, Inc. today announced that it has been awarded a contract from Premier Inc., one of the nation``s largest medical group-purchasing organizations, covering Cardiac Science``s line of external defibrillator products. The agreement offers access to Premier``s 1,500 independent hospital and hundreds of healthcare facility affiliates located around the United States.

Under the contract, Cardiac Science will provide Premier members special incentives and pricing when purchasing Powerheart(R) AEDs as well as Powerheart(R) Cardiac Rhythm Module(R) (CRM) a fully-automatic therapeutic bedside monitor-defibrillator designed for medically-supervised environments such as hospitals, outpatient medical clinics and physician offices.

The unique Powerheart CRM was accepted under Premier``s "Technology Breakthroughs" program, which reviewed and compared Powerheart technology with traditional external defibrillator products used for medically supervised resuscitation prior to awarding the contact.

CRM is the only FDA-cleared device on the market that can prophylactically monitor cardiac patients at risk of sudden cardiac arrest and when necessary, automatically and instantly provide lifesaving defibrillation therapy without human intervention.

Cardiac Science Chairman and CEO Raymond W. Cohen said, "The Premier contract provides us with a great opportunity to sell AEDs to Premier hospitals and more importantly, create awareness and demand for our in- hospital Powerheart technology and the protection of patients in the hospital environment."

Cohen added, "We see the Powerheart CRM as being analogous to providing the same protection that an implantable defibrillator would, except in this case, the device provides temporary protection to cardiac patients during their hospitalization stay. Standard external defibrillator products used in hospitals today do not offer comparable technology that allows for prophylactic attachment to cardiac patients and immediate therapy without human intervention. Powerheart technology has been proven to significantly reduce the response time from the onset of a life-threatening arrhythmia to first shock thereby improving the chance of survival for hospitalized cardiac patients who suffer cardiac arrest."

[Dolocher]

Hoffentlich hält der momentane kurzfristige Aufwärtstrend an,die News sprechen auf jeden Fall dafür und auch fundamental sieht es weiterhin sehr positiv aus,wenn man mal nur die Verträge aus den letzten Wochen betrachtet,sollten wir potenzial bis 7-8$ haben...die 5$ sind bereits in Sichtweite

[Dolocher]

Heute auf 52 Wochen-Hoch geschlossen

[udoernst]

Ja, wenn das so weiter geht, erreichen die mein kursziel von $ 8.- schon in diesem Quartal....

[Teerwerk]

Endlich geht es aufwärts mit dieser tollen Aktie.

[Teerwerk]

Haltet diese Aktie weiterhin. Denn es kann nur noch nach oben gehen.

[Dolocher]

@udoernst

ich glaube Du schiesst mit Deiner Prognose schon etwas übers Ziel hinaus aber auf Jahressicht halte ich 8$ auch durchaus für möglich,falls es schneller geht,werde ich mich auch nicht ärgern
Auf jeden Fall ist jeder Investierte gut beraten,jetzt kein Stück aus der Hand zu geben,denn die Aussichten sind besser als je zuvor...

[messenger777]

o.k.dann verkauf ich auch kein stück

[Lekaro]

Wie werden wohl die nächsten Zahlen ausfallen?

IRVINE, Calif., Jan. 26 /PRNewswire-FirstCall/ -- Cardiac Science, Inc. , a leading manufacturer of life-saving automated public-access defibrillators (AEDs), today announced that it has been awarded a multi-year contract by the U.S. Environmental Protection Agency (EPA) to supply Powerheart(R) AEDs and provide comprehensive training and AED program management services for its facilities around the nation.

The EPA purchased 105 Powerheart(R) AEDs and 105 Heartsafe(TM) Workplace Programs for deployment in 13 facilities in the U.S. and contracted with Cardiac Science to provide medical direction, AED/CPR training for approximately 130 EPA employees and ongoing bi-annual recertification. The contract is valued in excess of $340,000.

Cardiac Science``s Chairman and CEO Raymond W. Cohen said that Federal agencies are coming into compliance with the requirements established in the Cardiac Arrest Survival Act of 2000 which directed the placement of AEDs in federal buildings around the nation.

"The government contracting process is fairly complex," said Cohen, "However, our ability to bundle AED products along with services into a single contract simplifies the process for these customers and gives us an advantage over our competitors. This EPA deployment is representative of the type of transactions we have secured or are in process of negotiating with other federal and state agencies."

[Lekaro]

State of California to Require AEDs in State Buildings
Thursday, January 29, 2004 01:30 AM ET

IRVINE, Calif., Jan. 29 /PRNewswire-FirstCall/ -- Cardiac Science, Inc. (Nasdaq: DFIB, news), a leading manufacturer of life-saving automated public-access defibrillators (AEDs), today announced that new California legislation seeking to place AEDs in all state facilities was signed into law by Governor Arnold Schwarzenegger on January 22, 2004. The new law, which was sponsored by Assemblywoman Shirley Horton (R-Chula Vista), requires the Department of General Services (DGS) to apply for federal funds for the specific purpose of purchasing AEDs and deploying them within all state-owned and leased buildings.



"The California legislative sponsors and the governor are to be applauded for this progressive public health bill that will surely lead to more lives saved," said Cardiac Science Chairman and CEO Raymond W. Cohen. "We anticipate other states will follow the lead of California and enact similar legislation further stimulating deployment of AEDs in communities across America."

California`s legislation comes on the heels of other federal and state legislation that has called for the deployment of AEDs in public and government workplaces as well as schools. Government facilities and/or school-related legislation have been enacted in New York, Pennsylvania, and recently in Nevada. Additional similar legislation is pending in several more states. Federal laws that have been enacted include the Federal Community Access to Emergency Defibrillation Act, which earmarked $55 million a year for five years for communities to purchase and place AEDs in public places; the Federal Teaching Children to Save Lives Act, which authorized $30 million over three years to allow local school districts to apply for federal grants to implement CPR and AED training programs; and the Federal Rural Access to Emergency Care Act, which authorized the federal government to expand access to AEDs in rural areas.

[Dolocher]

Cardiac Science, GE Medical in agreement
Cardiac Science, GE Medical in agreement

Cardiac Science (Irvine, California) and GE Medical Systems Information Technologies (Milwaukee, Wis consin), the healthcare IT business of General Electric, said they have signed multi-year strategic OEM, distribution and development agreements under which GE will market Cardiac Science automated external defibrillators (AEDs) and fully-automatic in-hospital defibrillator-monitors (CRMs) under the GE name in Europe, Asia, the Middle East and other international markets.

Under the agreements, Cardiac Science also will manufacture a line of biphasic external defibrillators for exclusive sale by GE.

[Dolocher]

AED equipment sold to major pharmaceutical firms
Cardiac Science, Inc., (DFIB), a manufacturer of automated public-access defibrillators (AEDs), announced that it has been awarded multiyear contracts by several pharmaceutical manufacturers, including AstraZeneca, Schering-Plough, and Wyeth to supply Powerheart AEDs and provide comprehensive training and program management services for facilities in various locations throughout the U.S. and Puerto Rico.

In aggregate, the total value of the contracts signed with London-based AstraZeneca, Plc., Kenilworth, New Jersey-based Schering-Plough, and Madison, New Jersey-based Wyeth exceeded $725,000.

More than 130 AEDs were shipped in the fourth quarter of 2003 to 30 facilities in 12 states and Puerto Rico. AED/CPR and first-aid training will be provided to all three customers beginning this month and program management services will continue in coming years and as far out as 2008 for one of the companies. Specific deployment locations of the AEDs varied by customer and will include executive offices, research and development facilities, manufacturing, shipping and receiving and administrative locations.

Cardiac Science`s chairman and CEO Raymond W. Cohen stated the company`s ability to establish long-term relationships with large multinationals with numerous facilities in locations in the U.S. and around the world has been greatly enhanced by the company`s recent acquisition of Complient. "The long-term nature of these contracts is especially encouraging," said Cohen. "Having the capability and infrastructure to successfully deliver a comprehensive package of AED equipment, training, and program management services has resulted in a powerful value proposition for large customers and significant recurring revenue opportunities for Cardiac Science. In just a few short months we have managed to position ourselves as an important partner to these organizations, not merely a one-off seller of a product. As a result we have already built a list of clients that will require products and services for years to come." This article was prepared by Biotech Week editors from staff and other reports. Copyright 2004, Biotech Week via NewsRx.com & NewsRx.net.

[Dolocher]

Cardiac Science’s new AED, the G3, is approved by FDA
Cardiac Science’s new AED, the G3, is approved by FDA

By KAREN YOUNG

Medical Device Daily Staff Writer

Cardiac Science (Irvine, California) has received 510(k) marketing clearance from the FDA for its new automated external defibrillator (AED), the Powerheart AED G3, which is designed to be an improvement over its current Powerheart AED model, first introduced in February 2002.

The new AED, brought to market in less than 12 months, will be targeted for use by lay persons as well as trained professionals in the corporate, public access, municipal, home and medical markets.

The company said the new G3 product line, which also will include a second, lower-price-point product called the FirstSave AED G3, costs about 30% less to produce than its current model. Cardiac Science said it expects “the higher gross profits to translate directly into operating profits.”

“It’s an important development for the company,” said Michael Gioffredi, vice president of sales and marketing at Cardiac Science.

Both products are focused at “the entire AED market,” Gioffredi said, with Cardiac Science following a dual product and pricing strategy allowing it to “sell the Powerheart AED G3 to customers who appreciate the full extent of its capabilities and features and are willing to pay for them, while also allowing us to compete at lower price points for those more price-conscious buyers with the FirstSave AED.”

With the FDA marketing clearance, Cardiac Science said it “will begin immediate shipments to end users, distributors and OEM partners.”

The Powerheart AED G3 offers features including one-button operation and intuitive voice commands that guide users through the rescue process, the company said. Using Cardiac Science’s patented RescueReady technology, the device is programmed to self-test daily to ensure that it always is functional in the event a rescue is necessary. The self-testing is completed for the presence and functionality of the device’s pre-connected defibrillation electrodes, self-contained battery system and hardware components to ensure reliability, the company said.

The Powerheart AED G3, like the FirstSave, also includes the company’s patented Rhythmx analysis software, which the company said can claim 100% sensitivity in “detecting life-threatening heart rhythms,” and its Star biphasic shocking engine which determines the amount of energy required to jump-start the heart based on each patient’s individual physiology.

The suggested retail price in the U.S. for Powerheart AED G3 is $2,495, while the suggested retail price for the FirstSave AED GE will be under $2,000, Gioffredi said.

“Powerheart AED is our flagship product with all the features that we currently provide, plus new, more intuitive voice commands that guide users through the rescue process, and packaged in a new more user-friendly design,” he said.

Gioffredi said Cardiac Science also has increased the battery warranty from two to three years for the Powerheart AED G3, noting that competitors, including Medtronic (Minneapolis, Minnesota), offer only a one-year battery warranty.

There are, of course, differences between the Powerheart AED G3 and the FirstSave product. First, Gioffredi said, that Powerheart customers will get “both visible and audible indicators” of the device’s rescue readiness in conjunction with the self-testing feature. FirstSave customers will only be provided with an audible indicator.

Secondly, the Powerheart user has the ability to program several of the device features into the product, including the energy protocol, or how the energy is administered to jump-start the heart.

“The FirstSave has no programmability, so when they buy that product its set by the manufacturer,” Gioffredi said, noting that certain medical directors endorse different protocols. And the FirstSave model has a one-year battery warranty compared to Powerheart’s three-year warranty.

Gioffredi said the product would be distributed through existing channels, including a direct sales force, indirect sales partners and OEM partners.

Last Thursday, Cardiac Science reported along with GE Medical Systems Information Technologies (Milwaukee, Wisconsin) that the companies had entered multiyear OEM, distribution and development agreements under which GE will market Cardiac Science AEDs and in-hospital defibrillator-monitors under the GE name in Europe, Asia, the Middle East and other international markets.

Also as part of the agreement, Cardiac Science will develop and manufacture a line of biphasic external defibrillators for exclusive sale by GE on a worldwide basis.

[Dolocher]

Cardiac Science Announces 2003 Fourth Quarter, Year-End Results


03-01-04 01:29 AM EST | 2003 AED Revenue Up 44% Over 2002

/PRNewswire-FirstCall/ -- Cardiac Science, Inc. (Nasdaq: DFIB), a leading manufacturer of life-saving automated public access defibrillators (AEDs) and provider of comprehensive AED/CPR training services, today reported revenue of $17.7 million for the fourth quarter ended December 31, 2003, an increase of 24 percent from the $14.3 million reported in the same quarter last year. In the quarter, the company also received new orders for AED/CPR training services in excess of $700,000, which will be recognized as revenue in future quarters as the services are delivered. Revenue for the full 2003 year increased 24 percent to $62.0 million from the $50 million in 2002, due primarily to the company`s expanding share of the growing worldwide market for AEDs.

Revenue from AED products and related accessories was $14.5 million, up 17 percent as compared to $12.4 million in the same period in 2002. Revenue for the quarter from AED/CPR training services and related products totaled $2.2 million resulting from the company`s October 21, 2003 acquisition of substantially all the assets of Complient Corporation. For the full year, sales of AEDs and related accessories totaled $55.3 million and were up 44 percent over 2002. The balance of revenue in the quarter was attributable to sales of the company`s patient monitoring and Powerheart(R) CRM in-hospital defibrillation product lines which totaled $1 million and $4.5 million for the full 2003 year.

In the fourth quarter the company recognized a one time, inventory impairment charge of $2.9 million related to its first generation Powerheart and CRM in-hospital defibrillators. This charge reflects a strategic decision to terminate the "no-cap" placement business model in U.S. hospitals, in favor of a capital sale model focused on key distribution relationships such as the company entered into with GE Medical Systems in late 2003.

Including the one time inventory impairment charge, the gross margin for the fourth quarter was 43.3 percent. Excluding the one time charge, the gross margin for the fourth quarter was 59.9 percent, up from 55.3 percent in the same period in 2002. For the full year, gross margin, excluding the one time charge, was 58.7 percent, up from 50.6 percent in the prior year. The increase in both periods, excluding the one time charge, was due to a higher mix of AED sales and the introduction of the new Powerheart(R) AED G3 product line released for commercial sale in August 2003.

The operating loss for the fourth quarter, inclusive of the one time charge, was $5.0 million. The fourth quarter operating loss, excluding the one time charge was $2.0 million, compared to an operating loss of $2.3 million in the corresponding 2002 period. For the full year 2003, the operating loss, including the one time charge was $7.1 million. Excluding the one time charge, the full year operating loss was $4.2 million compared to $10.8 million in 2002, a reduction of 61 percent.

The net loss in the 2003 fourth quarter was $6.5 million, or $0.08 loss per share, including the $2.9 million inventory impairment charge, compared to $3.7 million, or $0.05 loss per share, in the corresponding 2002 period. The net loss for 2003 decreased to $12.5 million, or $0.18 loss per share, in 2003, from a loss of $15.1 million, or $0.22 loss per share, in 2002. Contribution to the net loss in the fourth quarter and full year from the one-time impairment charge was $0.04 loss per share.

Cardiac Science Chairman and CEO Raymond W. Cohen said that the AED product line, led by the Powerheart AED G3, continued to be the principal revenue driver during the quarter and that growth was fueled and complemented by the addition of AED/CPR training services which the company began marketing to corporate and government customers beginning in the middle of the fourth quarter. He noted that sales of AED products, accessories and training services totaled $16.7 million or 94 percent of revenue in the fourth quarter.

Cohen said, "As evidenced by our 44 percent increase in 2003 AED revenue, Cardiac Science made significant gains in market share and is now positioned as a major player in the worldwide AED market. Worldwide shipments of AEDs increased to over 29,000 units, up 68 percent from last year. The two strongest sectors within the domestic AED market were corporate and government workplace facilities. Combined, these segments accounted for over 50 percent of the total number of AEDs sold in the United States. Internationally AED sales, particularly in Japan and the U.K., continued to post strong gains and accounted for nearly 20 percent of all AED revenue in 2003."

"Despite some decline in AED selling prices last year we significantly improved our AED gross margins based on our strong direct sales effort and product development and manufacturing initiatives that yielded a lower cost of goods on our AED G3 product line. Since late October, management has worked diligently to integrate the AED/CPR training business purchased from Complient. Over the past few months we reduced headcount by two thirds, improved the efficiency of the operations, streamlined the service offering, and trained our U.S. sales force to effectively sell a comprehensive package of products and services. These initiatives have resulted not only in very respectable gross margins, but moreover, an ability to capture large multi- year, multi-facility contracts with major U.S. companies and federal agencies. We are extremely optimistic that continued improvement in margins, combined with operating leverage and the benefits of a more focused product line along with continued revenue growth will allow us reach operating profitability in the near term, and post solid profits in 2004 and beyond."

Financial Guidance for 2004

The company also announced two strategic changes for the year 2004. In order to increase resource focus on its core AED and hospital defibrillation markets, the company is exiting from two lower gross margin product lines: the Diascope(R) patient monitoring line, which was sold primarily in the Middle East and Asia, and the wholesale training equipment and supplies business, including mannequins, CPR Prompt devices and other ancillary items acquired from Complient Corporation. Since those business lines are currently contributing to revenue, the company is changing its 2004 guidance to reflect, conservatively, no additional revenue contribution from these product lines.

In light of these changes, the company anticipates 2004 revenue of between $85 and $100 million, of which approximately 95 percent will be attributable to the sale of AED products and training services. The company`s 2004 revenue guidance is based on a projected 32 to 45 percent increase in sales of its core AED product line, and assumes that AED/CPR training services will contribute between $10 and $15 million in revenue. Sales of the company`s in- hospital defibrillator product line are anticipated to generate between $2 and $5 million in revenue. The company anticipates that 45 percent of the full year revenue will fall in the first six months of 2004.

The company expects gross margins in the first half of the year to range between 61 to 63 percent, and increase in the second half to between 63 and 65 percent. This increase in gross margin guidance is based on exiting lower margin product lines, further identified reductions in the cost of its AEDs, and enhanced margins related to the AED/CPR training and services offering.

The company expects its operating expenses for 2004 to range from $51 to $53 million, resulting in operating income of $3.0 to $10.0 million. Based on this range of operating income, net income/loss would range from a loss of $3.8 million or $0.05 loss per share, to net income of $3.3 million or an estimated $0.04 per share.

About Cardiac Science

Cardiac Science develops, manufactures and markets Powerheart(R)-brand public-access defibrillators (AEDs) and offers comprehensive AED/CPR training services that facilitate successful deployments. The Company also makes the Powerheart(R) CRM(TM), the only FDA-cleared therapeutic patient monitor that instantly and automatically treats hospitalized cardiac patients who suffer life-threatening heart rhythms. Cardiac Science manufactures its AED products on a private label basis for other leading medical companies. The Company`s AEDs and CRM products are marketed in the United States by its 55-person direct sales force, numerous domestic distribution channel partners and by international distributors in more than 50 countries around the world. For more information, please visit www.cardiacscience.com.

This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, from time to time the company, or its representatives, have made or may make forward-looking statements orally or in writing. The words "estimate," "potential," "intended," "expect," "anticipate," "believe," and similar expressions or words are intended to identify forward looking statements. Such forward-looking statements include, but are not limited to the achievement of future revenue growth and operating profitability. Cardiac Science cautions that these statements are subject to substantial risks and uncertainties and are qualified by important factors that could cause actual results to differ materially from those reflected by the forward-looking statements and should not be relied upon by investors when making an investment decision. Information on these and other factors is detailed in the Company`s Form 10-K for the year ending December 31, 2002, subsequent quarterly filings, and other documents filed by the Company with the Securities and Exchange Commission.

Contact: Matt Clawson (Investors), or Roderick de Greef
Len Hall (Media) Chief Financial Officer
Allen & Caron Inc Cardiac Science, Inc.
[phone] 949-797-3800
[e-mail] [e-mail]
[e-mail]


Cardiac Science, Inc.
Consolidated Statement of Operations
(Unaudited)
In thousands, except share and per share amounts

Three Months Ended Twelve Months Ended
December 31, December 31,
2003 2002 2003 2002

Revenue $17,703 $14,253 $61,982 $50,043
Cost of Goods Sold 7,099 6,373 25,626 24,737
Inventory Impairment 2,917 -- 2,917 --
Gross Profit 7,687 7,880 33,439 25,306

Operating Expenses:
Sales and Marketing 5,689 5,354 18,616 17,325
Research and Development 1,599 1,295 5,538 6,053
General and Administrative 4,920 3,001 14,720 11,474
Amortization of Intangibles 445 502 1,656 2,111
Gain on Settlement -- -- -- (832)
Total Operating Expenses 12,653 10,152 40,530 36,131

Operating Loss (4,966) (2,272) (7,091) (10,825)

Interest and other
income/(expense) (1,525) (1,351) (5,891) (4,142)

Operating Loss before
provision for income taxes (6,491) (3,623) (12,982) (14,967)
Provision for income taxes -- -- -- --
Loss before minority interest (6,491) (3,623) (12,982) (14,967)

Minority interest in
subsidiary -- (7) (48) (33)
Income/(loss) from
discontinued operations -- (52) 493 (52)
Net loss $(6,491) $(3,682) $(12,537) $(15,052)

Net loss per share (basic
and diluted) $(0.08) $(0.05) $(0.18) $(0.22)

Weighted average number of
shares used in the
computation of net loss
per share 77,927,862 67,111,281 69,848,014 67,199,419


Cardiac Science, Inc.
Condensed Consolidated Balance Sheets
In thousands

December 31, December 31,
2003 2002
(Unaudited)
ASSETS
Current Assets:
Cash and cash equivalents $8,871 $15,598
Accounts receivable, net 20,410 10,986
Inventory 9,575 5,918
Prepaid expenses 2,154 2,098
Assets held-for-sale -- 1,161
Total Current Assets 41,010 35,761
Property and equipment, net 7,003 5,206
Goodwill and other intangibles, net 151,485 106,546
Other assets 3,503 6,407
203,001 153,920

LIABILITIES AND STOCKHOLDERS` EQUITY
Current Liabilities:
Accounts payable 8,955 6,921
Accrued expenses and other
current liabilities 9,074 7,596
Liabilities held-for-sale -- 2,067
Total current liabilities 18,029 16,584
Long term notes payable 46,481 41,054
Other long term liabilities 900 1,112
Minority interest -- 900
Total stockholders` equity 137,591 94,270
$203,001 $153,920

SOURCE Cardiac Science, Inc.
SOURCE Cardiac Science, Inc.

[Dolocher]

Cardiac Science 4Q Loss Widens On Impairment Charge >DFIB




03-01-04 03:05 AM EST
IRVINE, Calif. (Dow Jones)--Cardiac Science Inc.`s (DFIB) fourth-quarter quarter loss widened despite higher revenue due to an inventory impairment charge.

In a press release Monday, the company said it posted a loss of $6.5 million, or 8 cents a share, compared with a loss of $3.7 million, or 5 cents a share, in the prior-year fourth quarter.

Results in the latest quarter included a $2.9 million charge related to Cardiac Science`s first-generation Powerheart and CRM in-hospital defibrillators.

The charge reflects that fact that the company is terminating the "no-cap" placement business model in U.S. hospitals, in favor of a capital sale model focused on key distribution relationships.

Revenue during the quarter ended Dec. 31, rose 24% to $17.7 million from $14.3 million, with revenue from AED products, or automated public access defibrillators, and related accessories up 17%, to $14.5 million.

Five analysts surveyed by Thomson First Call Cardiac Science produced an earnings estimate of breakeven results for the fourth quarter.

For 2004, Cardiac Science expects revenue of $85 million to $100 million, which reflects its decision to exit two lower-margin product lines: the Diascope patient monitoring line and the wholesale training equipment and supplies business.

The company said it is exiting the lines in order to increase resource focus on its core AED and hospital defibrillation markets.

Results are expected to come in between a loss of $3.8 million, or 5 cents a share, and net income of $3.3 million, or 4 cents a share.

Analysts surveyed by First Call forecast year earnings of 6 cents a share on revenue of $100.48 million.

Cardiac Science Inc. - Irvine, Calif.
4th Quar Dec. 31:
2003 2002
Revenue $17,703,000 $14,253,000
Net income a (6,491,000) (3,682,000)
Avg shrs (diluted) 77,927,862 67,111,281
Shr earns
Net income a (.08) (.05)
Year:
Revenue 61,982,000 50,043,000
Net income a,b (12,537,000) c (15,052,000)
Avg shrs (diluted) 69,848,014 67,199,419
Shr earns
Net income a,b (.18) c (.22)

Figures in parentheses are losses.

a. Includes $2.9 million inventory impairment charge.

b. Includes $493,000 income from discontinued operations.

c. Includes $832,000 gain on settlement.

Company Web site: http://www.cardiacscience.com

-Dorothea Degen; Dow Jones Newswires; 201-938-5400


Dow Jones Newswires
03-01-04 0305ET
Copyright (C) 2004 Dow Jones & Company, Inc. All Rights Reserved.

[messenger777]

Cardiac Science Receives FDA 510(k) Clearance to Market Its New Powerheart(R) G3 Fully-Automatic Public Access Defibrillator
7/2/04


IRVINE, Calif., Jul 2, 2004 /PRNewswire-FirstCall via COMTEX/ --
Cardiac Science, Inc. (Nasdaq: DFIB) today announced that the U.S. Food and Drug Administration has granted the Company 510(k) clearance to market its new Powerheart(R) G3-Automatic automated external defibrillator (AED), the first fully-automatic AED in the Powerheart product line. This new generation AED has been designed specifically for public places, corporate settings and in-home use by consumers.

A rescuer need only listen to the Powerheart`s detailed voice instructions explaining how to attach the device to the heart attack victim to potentially save a life. There are no buttons to push or additional action required since the Powerheart analyzes the patient`s condition to detect a life-threatening heart rhythm and, if appropriate, automatically delivers a potentially life-saving defibrillation shock(s) to restore the heart to a normal rhythm.

Cardiac Science Chairman and CEO Raymond W. Cohen said, "Simplicity in design, robust Rescue-Ready(R) self-testing technology, advanced detection algorithms in a package that promises maintenance-free operation combine to make the Powerheart G3-Automatic the easiest to use AED on the market -- bar none. Cardiac Science continues to innovate and introduce new products based on our proprietary and patented technology at affordable and competitive prices. Customers appreciate the distinctions in our AED products and services and we believe that these distinctions are ultimately more important to customers than anything our larger competitors can offer. Over time, we envision this will play out in terms of AED market share leadership for Cardiac Science."

The company announced in December that it had been granted a U.S. patent that covers a publicly-available portable defibrillator capable of being used by a bystander to automatically deliver life-saving defibrillation shock(s) to a heart attack victim.

About Automated External Defibrillators and the Worldwide Market

AEDs are designed to quickly and easily provide a life-saving defibrillation shock to restore normal heart rhythm to a sudden cardiac arrest victim. AEDs are being used by first responders such as police, fire and ambulance personnel, and are also being widely deployed at places where people gather or work, such as airplanes, airports, train stations, corporate offices, factories, schools, shopping malls, stadiums, restaurants, health clubs, casinos and federal, state, municipal government buildings as well as commercial office buildings. It is estimated that the annual worldwide market for AEDs will grow to four or five fold by the end of the decade up from $200 million in 2003.

About Cardiac Science

Cardiac Science develops, manufactures and markets the Powerheart brand, automated public access defibrillators (AEDs), and offers comprehensive AED/CPR training and AED program management services that facilitate successful deployments. The company also makes the Powerheart CRM(TM), the only FDA-cleared therapeutic patient monitor that instantly and automatically treats hospitalized cardiac patients who suffer life-threatening heart rhythms. Cardiac Science also manufactures its AED products on a private label basis for other leading medical companies. For more information please visit www.cardiacscience.com or call 1.949.797.3800.

This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, from time to time the company, or its representatives, have made or may make forward looking statements orally or in writing. The words "estimate," "potential," "intended," "expect," "anticipate," "believe," and similar expressions or words are intended to identify forward looking statements. Such forward-looking statements include, but are not limited to the achievement of future revenue growth and the lowering of the company`s breakeven revenue level by the third quarter. Cardiac Science cautions that these statements are subject to substantial risks and uncertainties and are qualified by important factors that could cause actual results to differ materially from those reflected by the forward-looking statements and should not be relied upon by investors when making an investment decision. Information on these and other factors is detailed in the Company`s Form 10-K for the year ending December 31, 2003, subsequent quarterly filings, and other documents filed by the Company with the Securities and Exchange Commission.

Contact: Matt Clawson (Investors) Kenneth Olson Len Hall (Media) Chief Technology Officer Allen & Caron Inc Cardiac Science, Inc. [phone] [phone] [e-mail] [e-mail] [e-mail]
SOURCE Cardiac Science, Inc.

investors, Matt Clawson, [e-mail], or media, LenHall, [e-mail], both of Allen & Caron Inc, [phone], forCardiac Science, Inc.; or Kenneth Olson, Chief Technology Officer of CardiacScience, Inc., [phone], [e-mail]
http://www.cardiacscience.com

[Holzofen]

Kann mir einer das ganze auf Deutsch erklären warum die Aktie so steigt vielen dank .